Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms guardian TM 10
- Sponsors Novo Nordisk
- 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2018 Planned End Date changed from 23 May 2019 to 22 Apr 2019.
- 05 Dec 2018 Planned primary completion date changed from 23 Apr 2019 to 25 Mar 2019.